source
- Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugsLast summer, zero biotechs made it onto the public markets as the industry weathered a seven-month dry spell for initial share sales. This time around, it's a summer IPO party as sixEndpoints · 12d ago↗ source
- GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 failCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.BioSpace · 12d ago↗ source
- Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilityInsmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…